Pinnacle Associates’s CRISPR Therapeutics CRSP Stock Holding History

Pinnacle Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,993	Closed	-$250K	–	846
2024 Q3	$250K	Buy	+3,993	New	+$203K	﹤0.01%	726
2024 Q2	–	Sell	-5,303	Closed	-$361K	–	820
2024 Q1	$361K	Buy	5,303 +1,310	+33%	+$93.8K	0.01%	653
2023 Q4	$250K	Buy	+3,993	New	+$221K	﹤0.01%	736
2023 Q3	–	Sell	-4,316	Closed	-$242K	–	815
2023 Q2	$242K	Buy	+4,316	New	+$245K	﹤0.01%	733
2022 Q4	–	Sell	-4,416	Closed	-$289K	–	763
2022 Q3	$289K	Buy	+4,416	New	+$320K	0.01%	606

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinnacle Associates's CRSP Position: Q4 2024 in Review

Pinnacle Associates sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 3,993 shares — an estimated $250K sold.

Pinnacle Associates first reported a position in CRSP in Q3 2022 and held it in 5 quarters. The position peaked at $361K in Q1 2024. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Pinnacle Associates reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Pinnacle Associates sold 3,993 CRISPR Therapeutics shares in Q4 2024, an estimated $250K.
Pinnacle Associates first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 5 quarters.
Pinnacle Associates's CRISPR Therapeutics position peaked at $361K in Q1 2024.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Pinnacle Associates's 13F filing for Q4 2024, filed 14 Feb 2025.